Viridian Therapeutics, Inc. (VRDN)
Viridian Therapeutics, Inc. (VRDN) is a healthcare company (biotechnology) based in the United States. The share price is $29.71, down 0.30% on the day, which values the company at $3.37B. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.
Key facts
- Share price
- $29.71−0.30% today
- Market value
- $3.37B
- Funk Score
- 54/100
- 200-week average
- $20.4046% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Viridian Therapeutics, Inc. in more detail
VRDN trades at -14.0× next year's expected earnings, 128.2× sales. It sits 46% above its 200-week average of $20.40.
Over the last five fiscal years Viridian Therapeutics, Inc. has compounded revenue 132.2% a year. Its Funk Score is 54 out of 100 (financial strength 5.6, profitability 2.5, growth 8.0, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.
1 of the superinvestors tracked here hold VRDN, including Julian and Felix Baker (0.2% of the portfolio).
Superinvestors holding VRDN
1 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors0.22% of portfolio · $43.8M · added · Q2 2026
Viridian Therapeutics, Inc. (VRDN): questions and answers
What is Viridian Therapeutics, Inc.'s market cap?
Viridian Therapeutics, Inc. is valued at $3.37B at a share price of $29.71.
Is VRDN above its 200-week moving average?
Yes. VRDN is 45.6% above its 200-week average of $20.40. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Viridian Therapeutics, Inc. growing?
Over the last five fiscal years Viridian Therapeutics, Inc.'s revenue grew 132.2% a year; over ten years revenue grew 28.6% a year.
Does VRDN pay a dividend?
Viridian Therapeutics, Inc. does not currently pay a regular dividend.
Which famous investors own VRDN?
In their latest quarterly filings, Julian and Felix Baker (0.2% of the portfolio) hold VRDN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Viridian Therapeutics, Inc. (VRDN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/VRDN
Underlying data: Yahoo Finance; company filings with the SEC.